Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review

  • ID: 1292068
  • SWOT Analysis
  • 63 pages
  • GlobalData
  • Novo Nordisk A/S
1 of 5

FEATURED COMPANIES

  • ALK-Abello AS
  • AstraZeneca Plc
  • Dansk Biotek
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Orexigen Therapeutics Inc
  • MORE
Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company’s product portfolio includes new-generation insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products, hormone replacement therapy and other serious chronic diseases. With subsidiaries in Europe, North America, Asia, Latin America, Africa, Middle East and Australia, the company markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Novo Nordisk AS Key Recent Developments

Feb 12, 2018: Novo Nordisk Plans $65M Expansion of Clayton Manufacturing Site
Feb 01, 2018: Novo Nordisk and Eskayef unite to manufacture modern insulin
Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies)
Dec 14, 2017: Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System
Dec 11, 2017: Torrent & Novo Nordisk India expand insulin manufacturing facility at Indrad

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ALK-Abello AS
  • AstraZeneca Plc
  • Dansk Biotek
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Orexigen Therapeutics Inc
  • MORE
Section 1 - About the Company
  • Novo Nordisk AS - Key Facts
  • Novo Nordisk AS - Key Employees
  • Novo Nordisk AS - Key Employee Biographies
  • Novo Nordisk AS - Major Products and Services
  • Novo Nordisk AS - History
  • Novo Nordisk AS - Company Statement
  • Novo Nordisk AS - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Novo Nordisk AS - Business Description
  • Business Segment: Biopharmaceuticals
  • Overview
  • Performance
  • Business Segment: Diabetes care and Obesity
  • Overview
  • Performance
  • Key Stats
  • Geographical Segment: International Operations
  • Target Markets
  • Performance
  • Geographical Segment: North America Operations
  • Target Markets
  • Performance
  • R&D Overview
  • Novo Nordisk AS - Corporate Strategy
  • Novo Nordisk AS - SWOT Analysis
  • SWOT Analysis - Overview
  • Novo Nordisk AS - Strengths
  • Novo Nordisk AS - Weaknesses
  • Novo Nordisk AS - Opportunities
  • Novo Nordisk AS - Threats
  • Novo Nordisk AS - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Novo Nordisk AS, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 12, 2018: Novo Nordisk Plans $65M Expansion of Clayton Manufacturing Site
  • Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies)
  • Dec 14, 2017: Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System
  • Dec 11, 2017: Torrent & Novo Nordisk India expand insulin manufacturing facility at Indrad
  • Dec 11, 2017: Torrent & Novo Nordisk India expand insulin manufacturing facility at Indrad
  • Nov 13, 2017: Novo Nordisk Selects Emerson to Help Bring Medication to Market More Quickly to Address Growing Diabetes Epidemic
  • Nov 01, 2017: Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017
  • Oct 31, 2017: New US study reveals key reasons why millions of people with obesity are not receiving adequate care
  • Sep 26, 2017: Novo Nordisk Teams Up with HITLAB to Challenge Innovators to Develop Voice-Activated Technology for Diabetes Care with $75,000 in Prizes
  • Aug 15, 2017: Changes in Novo Nordisk Executive Management
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Novo Nordisk AS, Key Facts
  • Novo Nordisk AS, Key Employees
  • Novo Nordisk AS, Key Employee Biographies
  • Novo Nordisk AS, Major Products and Services
  • Novo Nordisk AS, History
  • Novo Nordisk AS, Subsidiaries
  • Novo Nordisk AS, Key Competitors
  • Novo Nordisk AS, Ratios based on current share price
  • Novo Nordisk AS, Annual Ratios
  • Novo Nordisk AS, Annual Ratios
  • Novo Nordisk AS, Annual Ratios
  • Novo Nordisk AS, Interim Ratios
  • Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Novo Nordisk AS, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Novo Nordisk AS, Performance Chart (2013 - 2017)
  • Novo Nordisk AS, Ratio Charts
  • Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Takeda Pharma A/S
  • Rezolute Inc
  • PEPTONIC medical AB
  • Orifarm Group A/S
  • Orexigen Therapeutics Inc
  • H. Lundbeck AS
  • GlaxoSmithKline Plc
  • Flowsion A/S
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Dansk Biotek
  • Billev Pharma ApS
  • AstraZeneca Plc
  • Arrow Pharma ApS
  • ALK-Abello AS
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll